Provided by Tiger Trade Technology Pte. Ltd.

INNOVENT BIO

98.050
+2.1502.24%
Volume:16.81M
Turnover:1.64B
Market Cap:171.10B
PE:208.62
High:99.350
Open:95.150
Low:94.800
Close:95.900
52wk High:112.700
52wk Low:69.550
Shares:1.75B
HK Float Shares:1.75B
Volume Ratio:1.98
T/O Rate:0.96%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.470
ROE:7.01%
ROA:2.23%
PB:7.05
PE(LYR):208.62
PS:9.31

Loading ...

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Yesterday

Movement Alert|INNOVENT BIO Rises 3.18% in Regular Trading, Strong Interim Results and New Drug Approval Boost Sentiment

Market Focus
·
Yesterday

Innovent Says Trispecific Antibody Ibi3003 Posts 84.6% ORR at Phase 1 RP2D in Relapsed/refractory Multiple Myeloma

Reuters
·
Sep 29

2026 Ims Oral Presentation: Innovent Announces Updated Phase 1 Clinical Data of Trispecific Antibody Ibi3003 (Gprc5d/Bcma/Cd3) in Patients with Relapsed or Refractory Multiple Myeloma

THOMSON REUTERS
·
Sep 29

US Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 28

Innovent Biologics Gets China Nod for Jaypirca to Treat Chronic Lymphocytic Leukemia

MT Newswires Live
·
Sep 28

Jaypirca® (Pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia (Cll) /Small Lymphocytic Lymphoma (Sll) Across All Lines of Therapy

Reuters
·
Sep 28

Innovent's Jaypirca (pirtobrutinib) wins NMPA approval for all-line CLL/SLL treatment in China

Stock News
·
Sep 28

Innovent Biologics - Jaypirca (Pirtrobrutinib) Approved in China for Cll/Sll Across All Lines of Therapy

THOMSON REUTERS
·
Sep 28

Movement Alert|INNOVENT BIO Falls 3.31% in Regular Trading, Trading at 96.35 HKD

Market Focus
·
Sep 28

Innovent Expands Phase 3 MarsLight-11 Trial of Ibi363/tak-928 to Include Non-Squamous NSCLC Patients

Reuters
·
Sep 28

Innovent Announces Expansion of Global Phase 3 Marslight-11 Study of Ibi363/Tak-928 (Alpha-Biased Il-2/Pd-1 Bispecific Fusion Protein) in Immunotherapy-Resistant Nsclc to Include Patients with Non-Squamous Nsclc

THOMSON REUTERS
·
Sep 28

Movement Alert|INNOVENT BIO Falls 3.29% in Regular Trading, Trading at 100.1 HKD

Market Focus
·
Sep 24

INNOVENT BIO Posts Robust Growth on Dual Momentum From Oncology and Integrated Product Lines

Deep News
·
Sep 23

Innovent to Present Phase 3 Interim Data for Cldn18.2 ADC Ibi343 in Third-Line Gastric Cancer at ESMO 2026

Reuters
·
Sep 23

Market Chatter: US Considers Rules Allowing American Investment in Chinese Drugs

MT Newswires Live
·
Sep 21

Citi Highlights Policy Boost for Innovative Drugs and Medical Devices, Names Key Sector Picks

Stock News
·
Sep 21

China's Roadmap for Pharmaceuticals May Support Sector Development

Dow Jones
·
Sep 21

HK Movers | Innovative Drug Stocks Rally Broadly; LEPU BIO, INNOCARE, AKESO Jump Over 7%

Tiger Newspress
·
Sep 21

Hong Kong Stocks Open Flat as Pharma Shares Lead Gains; Innovent Rises Nearly 2%

Stock News
·
Sep 21